Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 4—April 2020
Synopsis

Imported Arbovirus Infections in Spain, 2009–2018

Francesca F. NormanComments to Author , César Henríquez-Camacho, Marta Díaz-Menendez, Sandra Chamorro, Diana Pou, Israel Molina, Josune Goikoetxea, Azucena Rodríguez-Guardado, Eva Calabuig, Clara Crespillo, Inés Oliveira, José-Antonio Pérez-Molina, Rogelio López-Velez, and for the Redivi Study Group
Author affiliations: Ramón y Cajal University Hospital, Madrid, Spain (F.F. Norman, C. Henríquez-Camacho, S. Chamorro, J.-A. Pérez-Molina, R. López-Velez); La Paz-Carlos III Hospital, Madrid (M. Díaz-Menendez, C. Crespillo); Vall d’Hebron-Drassanes, Barcelona, Spain (D. Pou, I. Molina, I. Oliveira); Cruces University Hospital, Bilbao, Spain (J. Goikoetxea); Asturias Central University Hospital, Oviedo, Spain (A. Rodríguez-Guardado); La Fe de Valencia University Hospital, Valencia, Spain (E. Calabuig)

Main Article

Table 1

Main characteristics of patients with arbovirus monoinfections included in study of arbovirus infections, Spain, 2009–2018*

Characteristic Immigrants, n = 23 VFR immigrants, n = 308 VFR travelers, n = 21 Travelers, n = 493 p value
Median age (IQR), y
25 (14-48)
40 (34-48)
29 (11-37)
35 (29-43)
<0.001
Sex, no. (%) <0.001
F 13(56.5) 240 (77.9) 10 (47.6) 263 (53.4)
M
10 (43.5)
68 (22.1)
11 (52.4)
230 (46.7)

Etiologic virus, no. <0.001
Dengue 14 93 9 340
Chikungunya 8 162 7 103
Zika
1
53
5
50

Region, no. (%)† <0.001
Sub-Saharan Africa 4 (17.4) 12 (3.9) 2 (9.5) 42 (8.5)
North America 0 0 0 2 (0.4)
Central America and Caribbean 5 (21.7) 94 (30.5) 9 (42.9) 128 (26.0)
South America 10 (43.5) 192 (62.3) 6 (28.6) 84 (17.1)
South-central Asia 3 (13.0) 6 (2.0) 0 61 (12.4)
Eastern Asia 0 0 0 2 (0.4)
Southeast Asia 1 (4.4) 4 (1.3) 3 (14.3) 166 (33.7)
Australasia 0 0 1 (4.8) 4 (0.8)
Europe
0
0
0
2 (0.4)

Median travel days, no. (IQR) 0 30 (27–55) 30 (21–75) 23 (15–50) <0.001
Median weeks until first consultation, no. (IQR) 1.2 (0.6–4.3) 2 (0.9–5.8) 2.6 (1.3–4.4) 1.1 (0.4–3.6) <0.001
Travel >30 d, no. (%) 0 135 (44.3) 10 (47.6) 164 (33.3) 0,.05
Pretravel advice, no. (%) 0 21 (6.9) 3 (14.3) 218 (44.3) <0.001
Immunosuppression, no. (%) 1 (4.4) 4 (1.3) 2 (9.5) 5 (1.0) 0.008

*IQR, interquartile range; VFR, visiting friends and relatives.
†Data from Red Cooperativa para el Estudio de las Infecciones Importadas por Viajeros e Inmigrantes
(+Redivi, http://www.redivi.es).

Main Article

Page created: March 17, 2020
Page updated: August 10, 2020
Page reviewed: August 10, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external